{"status": "OK", "response": {"docs": [{"type_of_material": "Op-Ed", "blog": [], "news_desk": "OpEd", "lead_paragraph": "When a drug works, patients and insurance companies should pay the full price of the drug. When it doesn\u2019t, they should pay nothing.", "headline": {"seo": "Pay Only for Drugs That Help You", "main": "Pay Only for Drugs That Help You", "kicker": "Op-Ed Contributor", "print_headline": "Pay Only for Drugs That Help You", "content_kicker": "Op-Ed Contributor"}, "abstract": "Op-Ed article by Kadmon Corporation founder Samuel D Waksal proposes a system in which health care providers and patients would only pay for drugs if they are effective; holds method would cut costs and create incentives for drug developers; points out a pay-for-response model would also fuel scientific innovation.", "print_page": "27", "word_count": "825", "_id": "515b6b0ffdc59278db009e83", "snippet": "When a drug works, patients and insurance companies should pay the full price of the drug. When it doesn\u2019t, they should pay nothing.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2012/03/07/opinion/pay-only-for-drugs-that-help-you.html", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Health Insurance and Managed Care", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Genetics and Heredity", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Biotechnology", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Cancer", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Reform and Reorganization", "is_major": "N", "rank": "7", "name": "subject"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Samuel"}], "original": "By SAMUEL D. WAKSAL"}, "document_type": "article", "pub_date": "2012-03-07T00:00:00Z", "section_name": "Opinion"}, {"type_of_material": "Blog", "blog": [], "news_desk": null, "lead_paragraph": null, "headline": {"main": "Electronic Health Records: A Study and Perspective", "kicker": "Bits Blog"}, "abstract": "A new study found that doctors with computerized records are more likely to order tests. The study is another piece of evidence, among many, in the debate surrounding electronic health records. But that debate is really about the best way to adopt the technology, and at what pace -- not whether moving from the paper records to the computer age makes sense.", "print_page": null, "word_count": "833", "_id": "4fd3a3bf8eb7c8105d8ed7bd", "snippet": "A new study found that doctors with computerized records are more likely to order tests. The study is another piece of evidence, among many, in the debate surrounding electronic health records. But that debate is really about the best way to adopt...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://bits.blogs.nytimes.com/2012/03/06/electronic-health-records-a-study-and-perspective/", "multimedia": [], "subsection_name": null, "keywords": [], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Steve", "lastname": "LOHR"}], "original": "By STEVE LOHR"}, "document_type": "blogpost", "pub_date": "2012-03-06T16:00:22Z", "section_name": "Technology"}, {"type_of_material": "Op-Ed", "blog": [], "news_desk": "OpEd", "lead_paragraph": "Statins are the popular choice for lowering cholesterol, but could result in a sharp increase in the incidence of Type 2 diabetes.", "headline": {"main": "The Diabetes Dilemma for Statin Users", "kicker": "Op-Ed Contributor", "print_headline": "The Diabetes Dilemma for Statin Users", "content_kicker": "Op-Ed Contributor"}, "abstract": null, "print_page": "", "word_count": "739", "_id": "53f437fe79881034aaf5af28", "snippet": "Statins are the popular choice for lowering cholesterol, but could result in a sharp increase in the incidence of Type 2 diabetes.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2012/03/05/opinion/the-diabetes-dilemma-for-statin-users.html", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Statins (Cholesterol-Lowering Drugs)", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Diabetes", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Cholesterol", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Crestor (Drug)", "is_major": "N", "rank": "5", "name": "subject"}], "byline": {"contributor": "", "person": [{"firstname": "Eric", "middlename": "J.", "lastname": "TOPOL", "rank": 1, "role": "reported", "organization": ""}], "original": "By ERIC J. TOPOL"}, "document_type": "article", "pub_date": "2012-03-05T00:00:00Z", "section_name": "Opinion"}], "meta": {"hits": 3, "offset": 0, "time": 24}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}